BUSINESSAug 5 · 16:52 UTCMARKETWATCHSteve Goldstein

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Danish company Novo Nordisk developed a highly lucrative GLP-1 weight-loss drug but lost market dominance to American rival Eli Lilly. The article questions Europe's ability to compete in the global economy as Eli Lilly outmaneuvered Novo Nordisk in the diet-drug market.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Novo NordiskorganizationEli LillyorganizationGLP-1 weight-loss drugstopicEuropeplaceUnited Statesplace

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 18 · 08:30 UTC
What’s next for GLP-1 weight loss drugs?
BUSINESSAug 5 · 12:40 UTC
Eli Lilly and Novo Nordisk raise profit outlook as weight-loss drug demand soars
BUSINESSJun 13 · 12:00 UTC
Drugmakers race to find a place in the next wave of obesity drugs
BUSINESSMay 6 · 07:25 UTC
Novo Nordisk says the Wegovy pill saw the fastest take-up in weight-loss drug history
HEALTHMay 18 · 05:00 UTC
Novo Nordisk’s next obesity battlefront: Winning beyond America
HEALTHJun 8 · 14:30 UTC
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage